Every 8-K that Tenon Medical, Inc. (TNON) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow TNON and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNON filings page.
Tenon Medical, Inc. (TNON) reported that it has fully repaid its outstanding original issue discount senior convertible promissory notes, which had an aggregate principal balance of approximately $5.16 million, on September 9, 2026, ahead of their September 11, 2026 maturity date. The Notes were issued on March 11, 2026.
The company states that this early repayment strengthens its balance sheet and removes the potential conversion of the Notes into common stock at a discount to market prices, which would have created dilution. Tenon highlights that eliminating this obligation provides greater financial flexibility to support commercialization of its SI Joint fusion systems and broader growth initiatives.
Tenon Medical, Inc. (TNON) entered into a securities purchase agreement with an institutional investor for a private placement of pre-funded and Series A warrants, which closed on August 31, 2026. The deal covers pre-funded warrants to purchase up to 597,610 shares of common stock at $5.019 per pre-funded warrant and Series A warrants to purchase up to 1,058,517 shares at an exercise price of $5.02 per share, generating gross proceeds of $2,999,404.59 (plus up to $597.61 upon pre-funded warrant exercise).
The Series A warrants are immediately exercisable for five years, subject to a 4.99%–9.99% beneficial ownership cap, while the pre-funded warrants are exercisable at $0.001 per share with a 9.99% cap. Tenon agreed to pay WallachBeth Capital a 7% cash fee on gross proceeds and to file a resale registration statement for the underlying shares within 15 days, targeting effectiveness within 45 days (or 75 days after a full SEC review). Tenon plans to use net proceeds for repayment of certain debt, working capital and general corporate purposes.
Tenon Medical, Inc. (TNON) filed an amended current report to correct details of a recently issued convertible note financing. The amendment clarifies that the company issued an aggregate principal amount of $5.16 million of 20% Original Issue Discount Senior Convertible Promissory Notes in a private placement, generating approximately $4.3 million in gross proceeds. The notes mature on September 11, 2026, with an option for the company to extend to December 11, 2026, and are convertible after six months at a price equal to 80% of the three-day VWAP, with a corrected floor price of $0.1567. If the maturity is extended, principal increases by 5%; any prepayment is at 102.5% of principal, and 15% of net proceeds from future securities financings must be used to prepay the notes. Tenon agreed to pay its placement agent a 7% cash fee plus $65,000 in expenses. The offering relied on Section 4(a)(2) and Regulation D/Rule 506(b) exemptions from registration.
Tenon Medical, Inc. (TNON) reports that on August 24, 2026 it received written notice from Nasdaq’s Listing Qualifications staff that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). Nasdaq has confirmed that this compliance matter is now closed, meaning the company’s common stock and warrants continue to be listed on The Nasdaq Stock Market LLC.
Tenon Medical, Inc. reported strong top-line growth but continued losses for the quarter ended June 30, 2026. Revenue was $1.3 million, up 127% from the prior-year quarter, driven by a higher number of surgical procedures and added revenue from the SImmetry®+ System. Gross profit rose to $0.8 million with a 64% gross margin, compared with 43% a year earlier, reflecting higher volume and better absorption of fixed production costs.
Operating expenses increased to $4.2 million, mainly from higher sales and marketing spending for commercial expansion and SImmetry®+ rollout, and greater research and development investment. Net loss widened to $4.1 million (basic and diluted loss of $12.35 per share). Cash and cash equivalents were $1.7 million at June 30, 2026, versus $3.8 million at year-end, while current liabilities rose sharply and stockholders’ equity moved to a $1.7 million deficit.
Subsequent to quarter end, Tenon closed a public offering with $4.2 million in gross proceeds and approximately $3.6 million in net proceeds, intended in part to repay outstanding $5.2 million convertible notes maturing September 11, 2026 (extendable to December 11, 2026). The company also received FDA 510(k) clearance for an updated Catamaran® SI Joint Fusion System and highlighted record monthly case volume in July 2026. Forward-looking language cites risks including its ability to continue as a going concern, raise additional capital, and maintain Nasdaq listing compliance.
Tenon Medical, Inc. approved and implemented a 1-for-35 reverse stock split of its common stock. A Certificate of Amendment was filed in Delaware on August 6, 2026, and the split became effective at 12:01 a.m. Eastern Time on August 10, 2026.
Every 35 shares of issued and outstanding common stock were automatically combined into one share, with fractional shares rounded up to the next whole share. The common stock continues to trade on the Nasdaq Capital Market under the symbol "TNON", with a new CUSIP number 88066N402.
Proportionate adjustments were made to stock options, warrants, equity plan reserves and restricted stock units. The company stated that the primary goal of the reverse split is to increase the per share market price of its common stock to meet the $1.00 average closing price requirement for continued listing on the Nasdaq Capital Market.
Tenon Medical, Inc. reported results of its 2026 Annual Meeting of Stockholders, where holders of 6,471,472 shares of voting stock, representing 52.98% of votes, were present, establishing a quorum. As of the June 8, 2026 record date, voting power included 11,849,674 common shares, 204,159 Series A preferred shares representing 255,184 votes, and 86,454 Series B preferred shares representing 108,074 votes.
Stockholders elected all director nominees—Richard Ferrari, Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle—to serve until the company’s 2026 annual meeting of stockholders. They also approved the auditor appointment, a Reverse Stock Split Proposal, a Debt Financing Proposal, a Future Financing Proposal, and an adjournment proposal, each by a majority of shares represented and entitled to vote.
Tenon Medical, Inc. reported that Nasdaq has notified the company it has regained compliance with the continued listing requirement to maintain at least $2.5 million in stockholders’ equity under Nasdaq Listing Rule 5550(b)(1), known as the Stockholders’ Equity Rule.
Nasdaq’s July 17, 2026 notice was based on Tenon’s July 10, 2026 report stating that the company met this rule following completion of a $4.2 million public offering of common stock and warrants on July 1, 2026. Tenon also notes that if it does not demonstrate compliance when it files its Form 10-Q for the quarter ending September 30, 2026, its common stock may be subject to delisting from Nasdaq, with any such decision subject to appeal.
Tenon Medical, Inc. reports that, following a public offering completed on July 1, 2026 that raised $4.2 million from sales of common stock and warrants, it believes it now satisfies Nasdaq’s minimum stockholders’ equity requirement for continued listing on The Nasdaq Capital Market as of July 10, 2026. Nasdaq will continue to monitor compliance and may delist the company if its Quarterly Report on Form 10‑Q for the period ending September 30, 2026 does not show compliance with this stockholders’ equity standard. The company also includes a cautionary statement highlighting that its expectations about ongoing compliance involve forward‑looking statements subject to risks and uncertainties.
Tenon Medical, Inc. completed a best efforts public offering of common stock, pre-funded warrants and common stock purchase warrants, raising gross proceeds of about $4.2 million at a combined public offering price of $0.38 per share (inclusive of the $0.001 pre-funded warrant exercise price).
The offering covered up to 11,052,631 shares of common stock (or pre-funded warrants in lieu) and 13,263,159 common warrants, each warrant initially exercisable at $0.38 per share. Tenon plans to use net proceeds to partially repay outstanding convertible notes and fund commercial expansion, research and development, clinical studies, inventory, and general corporate purposes.
WallachBeth Capital LLC acted as sole placement agent, earning a 6.5% cash fee and a 1% expense allowance on gross proceeds, plus warrants to purchase 331,579 shares. The company agreed to short-term restrictions on additional equity issuance and variable-rate transactions, and its executives and directors entered 60-day lock-up agreements.
Tenon Medical, Inc. updated its leadership compensation and extended its executive chairman’s consulting agreement. The board’s Compensation Committee approved a 2026 Executive Compensation Plan that raises annual base salaries for CEO Steven M. Foster to $420,000, CFO Kevin Williamson to $330,750, and COO Richard Ginn to $304,500, each reflecting a 5% increase effective March 1, 2026. The plan also increases their annual bonus opportunities, with Mr. Foster eligible for 50% of base salary and Mr. Williamson and Mr. Ginn each eligible for 35%, all tied to mutually agreed milestones. In addition, they may earn a second milestone-based bonus of up to $100,000, $70,000, and $50,000, respectively. Separately, the company amended Executive Chairman Richard Ferrari’s consulting agreement, extending it for one year from May 7, 2026 to May 6, 2027, with compensation of $45,000 per quarter, or $180,000 annually.
Tenon Medical, Inc. reported that its Board of Directors approved Amendment No. 1 to the company’s Bylaws, effective June 10, 2026. The amendment lowers the stockholder meeting quorum requirement from a majority of eligible votes to not less than 33 1/3% of votes entitled to be cast, consistent with Nasdaq Listing Rule 5620.
The amendment also revises voting provisions so that holders of shares representing not less than a majority of the votes present at a meeting, rather than a majority of all outstanding shares, may decide that voting must be by written ballot and overseen by inspectors of election.
Tenon Medical, Inc. reported receiving a Nasdaq notice that it no longer meets the Nasdaq Capital Market’s minimum stockholders’ equity requirement. Nasdaq Listing Rule 5550(b)(1) requires at least $2,500,000 of stockholders’ equity, while the company reported $1,895,000 as of March 31, 2026.
Tenon has 45 days, until July 6, 2026, to submit a plan to regain compliance, and Nasdaq may grant up to 180 days from the notice date to do so. The notice does not immediately affect trading of the company’s common stock, but failure to regain compliance could eventually lead to delisting, subject to appeal rights before a Nasdaq Hearings Panel.
Tenon Medical reported strong top-line growth for the first quarter of 2026 while remaining unprofitable. Revenue reached $1.4 million, up about 90% from $0.7 million a year earlier, driven by broader adoption of its Catamaran and SImmetry+ SI joint fusion systems.
Gross profit rose to $0.9 million, with gross margin expanding from 44.5% to 68.5%, reflecting better overhead absorption. Operating expenses increased modestly to $4.2 million, and net loss narrowed slightly to $3.5 million, or $0.31 per share, from $3.6 million, or $1.01 per share.
Cash and cash equivalents were $4.6 million as of March 31, 2026, versus $3.8 million at year-end 2025, aided by a $4.3 million senior convertible note private placement completed in March. Total liabilities nearly doubled to $10.9 million, including $3.5 million of convertible notes and a new derivative liability, reducing stockholders’ equity to $1.9 million.
Tenon Medical, Inc. reported strong growth for the fourth quarter and full year 2025 while remaining unprofitable. Fourth quarter 2025 revenue reached $1.5 million, up 92% from $0.8 million a year earlier, with gross profit of $1.0 million and gross margin improving to 69% from 46%.
For the year ended December 31, 2025, revenue was $3.9 million, a 20% increase from $3.3 million, and gross profit was $2.4 million, or 60% of revenue, up from $1.7 million and 52%. Operating expenses for 2025 were $15.2 million, roughly flat with $15.5 million in 2024, leading to a narrower net loss of $12.6 million, or $1.70 per share, compared with a $13.7 million loss, or $11.26 per share. Cash and cash equivalents were $3.8 million as of December 31, 2025, down from $6.5 million, and the company reported no debt. Management highlighted FDA 510(k) clearance and initial procedures for its next-generation SImmetry+ SI Joint Fusion System as key milestones supporting future growth.
Tenon Medical, Inc. entered into securities purchase agreements for $4.3 million aggregate principal amount of 20% original issue discount senior convertible promissory notes in a private placement with accredited investors. The notes mature on September 11, 2026, with an option to extend to December 11, 2026, which increases the outstanding principal by 5%. After six months, they are convertible into common stock at a price equal to 80% of the volume-weighted average price over the three trading days before conversion, subject to adjustment. Any prepayment is at 102.5% of principal, and 15% of net proceeds from future securities financings must be used to prepay the notes. WallachBeth Capital LLC acted as placement agent, earning a 7% cash fee on gross proceeds plus $65,000 in expenses. Tenon expects to use net proceeds for commercial expansion, product development, clinical studies, working capital and general corporate purposes. The offering relied on exemptions from registration under Section 4(a)(2) and Regulation D/Rule 506(b).
Tenon Medical, Inc. has been notified by Nasdaq that its common stock failed to meet the minimum closing bid price of $1.00 per share for 30 consecutive business days between January 9 and February 24, 2026, triggering a deficiency under Nasdaq’s bid price rule.
The company has 180 calendar days, until August 24, 2026, for its stock to close at or above $1.00 for at least 10 consecutive business days to regain compliance. If it still fails, Tenon may qualify for an additional 180-day period if it meets other Nasdaq listing standards and formally indicates how it plans to cure the deficiency, potentially through a reverse stock split.
Tenon’s shares continue to trade on The Nasdaq Capital Market under the symbol “TNON” while the company evaluates its options. However, failure to regain or maintain compliance could ultimately lead to delisting, though the company would have the right to appeal any delisting determination.
Tenon Medical, Inc. reported preliminary unaudited revenue ranges showing strong growth for 2025. Fourth quarter 2025 revenue is expected between $1.45 million and $1.48 million, which the company says is about 90% higher year over year compared with the fourth quarter of 2024.
For full year 2025, Tenon expects unaudited revenue between $3.91 million and $3.94 million, representing roughly 20% year-over-year growth versus 2024. The company plans to release full financial results after market close on March 19, 2026 and will host a conference call that day at 4:30 p.m. Eastern Time to discuss the results in more detail.
Tenon Medical, Inc. entered into securities purchase agreements with accredited investors to sell 2,217,904 shares of common stock and accompanying warrants at a combined price of $1.285 per share and warrant. The warrants have an exercise price of $1.16 per share and a three-year term. The offering closed with the issuance of 2,217,904 shares and warrants to purchase 2,217,904 shares, providing approximately $2.85 million in gross proceeds that the company plans to use for working capital and general corporate purposes. Senior executives, including the CEO, CCO, and Chief Innovation Officer, participated as purchasers. The company must file a registration statement for the shares and warrant shares within 30 days, and the transaction was conducted as an unregistered private placement under Section 4(a)(2) and Regulation D.
Tenon Medical, Inc. filed an Amendment No. 1 to Form 8-K to add required financial information related to its previously reported acquisition of substantially all assets of SiVantage, Inc. The amendment updates Item 9.01 to present the acquired business’s financial statements and the company’s unaudited pro forma financials.
Exhibit 99.1 includes SiVantage’s audited financial statements for the year ended December 31, 2024 and unaudited financial statements for the six months ended June 30, 2025. Exhibit 99.2 provides an unaudited pro forma condensed balance sheet as of June 30, 2025 and unaudited pro forma condensed statements of operations for the year ended December 31, 2024 and the six months ended June 30, 2025. The amendment does not otherwise modify or update the original report.
Tenon Medical, Inc. reported an unregistered issuance of 866,642 restricted stock units (RSUs) to its directors and officers under the company’s 2022 Equity Incentive Plan.
The RSUs vest in two equal tranches, with 50% on January 1, 2026 and 50% on July 31, 2026, and each RSU will convert into one share of common stock upon vesting. The issuance was made in reliance on Section 4(a)(2) of the Securities Act as a private offering.
Tenon Medical, Inc. filed an 8-K dated September 23, 2025 that lists its publicly traded securities and records signatures and share-count figures for several named officers and directors. The document references Common Stock (par value $0.001) trading under the symbol TNON and Warrants trading under TNONW on The Nasdaq Stock Market. Individual entries show numeric holdings for Steven Foster, Richard Ginn, Stephen Hochschuler, MD, Ivan Howard, Kristine Jacques, and Robert Weigle, and the filing is executed by Steven M. Foster in his capacity as Chief Executive Officer and President.